Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405108 | 0.86 | ATM (0.38) | EPHX2ATMKDM4EKMT2ATDP1 | |
| SCHEMBL2866853 | 0.84 | MAPT (0.36) | EPHX2ATMKDM4EKMT2ATDP1 | |
| SCHEMBL2863746 | 0.83 | EPHX2 (0.40) | EPHX2KMT2ATDP1ALDH1A1PPARA | |
| SCHEMBL2859668 | 0.81 | GSK3B (0.37) | EPHX2CA2 | |
| SCHEMBL2860862 | 0.81 | LTB4R (0.36) | EPHX2TDP1POLBTSHRNPC1 | |
| SCHEMBL2861331 | 0.81 | MAPT (0.43) | EPHX2PPARACA2MAPT | |
| SCHEMBL2859926 | 0.80 | CA2 (0.45) | CA2 | |
| SCHEMBL10042986 | 0.80 | EPHX2 (0.54) | EPHX2KDM4EKMT2AALDH1A1HPGD | |
| SCHEMBL2866713 | 0.79 | EPHX2 (0.34) | EPHX2ATMKDM4EKMT2ATDP1 | |
| SCHEMBL2861474 | 0.78 | DYRK1A (0.35) | EPHX2KMT2APPARASMN1; SMN2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723366-B2 | Azole compounds as malonyl-CoA decarboxylase inhibitors for treating metabolic diseases | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-25 | — | — | US | disclosed |
| US-7723366-B2 | Azole compounds as malonyl-CoA decarboxylase inhibitors for treating metabolic diseases | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-25 | — | — | US | disclosed |
| US-7723366-B2 | Azole compounds as malonyl-CoA decarboxylase inhibitors for treating metabolic diseases | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-25 | — | — | US | disclosed |
| EP-1379243-B1 | METHODS FOR TREATING METABOLIC DISEASES USING MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-09-09 | — | — | EP | disclosed |
| EP-1379243-B1 | METHODS FOR TREATING METABOLIC DISEASES USING MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-09-09 | — | — | EP | disclosed |
| US-20040082564-A1 | Methods for treating metabolic diseases using malonyl-coa decarboxylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1379243-A1 | METHODS FOR TREATING METABOLIC DISEASES USING MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002066034-A1 | METHODS FOR TREATING METABOLIC DISEASES USING MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082564-A1 | Methods for treating metabolic diseases using malonyl-coa decarboxylase inhibitors | ME1, ME3, ME2 | EPHX2 904/4885ATM 2255/4885KDM4E 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.